Armata Pharmaceuticals Inc

Armata Pharmaceuticals announced that the U.S. FDA has agreed to its Initial Pediatric Study Plan for AP-SA02, a bacteriophage therapeutic for complicated Staphylococcus aureus bacteremia. The plan allows Armata to defer pediatric studies until adult safety and efficacy data are available from the planned Phase 3 program, expected to begin in the second half of 2026. Following the adult study, a single multicenter open-label pediatric trial will assess safety, tolerability, and clinical outcomes. AP-SA02 has received Qualified Infectious Disease Product and Fast Track designations from the FDA, and positive Phase 2a results were presented at IDWeek 2025. Armata's stock closed Friday at $4.26, down 11.80%, and was at $4.32 in pre-market trading, up 1.41%.

Armata Pharmaceuticals has secured an additional $2.5 million from the Department of Defense to advance its lead antibacterial candidate AP-SA02. The funding is part of a multi-year research and development agreement initially awarded $15 million in 2020 by the Defense Health Agency and Joint Warfighter Medical Research Program, bringing the total award to $28.7 million. The non-dilutive capital will support activities required to initiate a Phase 3 trial in the second half of 2026 for AP-SA02 as an adjunct treatment for complicated Staphylococcus aureus bacteremia. CEO Deborah Birx emphasized the DoD's continued partnership in developing the program.

Armata Pharmaceuticals received Fast Track Designation from the U.S. Food and Drug Administration for AP-SA02, its intravenously administered multi-phage therapy for complicated Staphylococcus aureus bacteremia. The designation is intended to expedite development and review of the candidate, which may qualify for rolling Biologic License Application submission, Accelerated Approval, and Priority Review. Armata plans to initiate a Phase 3 superiority study in the second half of the year and has secured a $25 million loan from Innoviva Strategic Opportunities to fund the program.